BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 15543092)

  • 1. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
    Lieberman R
    Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers and meaning of primary treatment failure.
    Swindle PW; Kattan MW; Scardino PT
    Urol Clin North Am; 2003 May; 30(2):377-401. PubMed ID: 12735513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
    Bantis A; Grammaticos P
    Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.
    Nakagawa T; Kollmeyer TM; Morlan BW; Anderson SK; Bergstralh EJ; Davis BJ; Asmann YW; Klee GG; Ballman KV; Jenkins RB
    PLoS One; 2008; 3(5):e2318. PubMed ID: 18846227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress and perspectives on prostate cancer biomarkers.
    Hatakeyama S; Yoneyama T; Tobisawa Y; Ohyama C
    Int J Clin Oncol; 2017 Apr; 22(2):214-221. PubMed ID: 27730440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.
    Saad F; Pantel K
    Future Oncol; 2012 Mar; 8(3):321-31. PubMed ID: 22409467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
    Crawford ED; DeAntoni EP; Ross CA
    J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.
    Small EJ; Roach M
    Semin Oncol; 2002 Jun; 29(3):264-73. PubMed ID: 12063679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
    Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
    J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
    Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
    Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for hormone-refractory prostate cancer.
    Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA testing for men at average risk of prostate cancer.
    Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.